Immune checkpoints and immunotherapy for colorectal cancer

Preet Paul Singh; Piyush K. Sharma; Gayathri Krishnan; A. Craig Lockhart

doi:10.1093/gastro/gov053

Immune checkpoints and immunotherapy for colorectal cancer

Preet Paul Singh
, Piyush K. Sharma
, Gayathri Krishnan
, A. Craig Lockhart

Division of Infectious Diseases

Research output: Contribution to journal › Review article › peer-review

86 Scopus citations

Abstract

Colorectal cancer (CRC) remains one of the major causes of death worldwide, despite steady improvement in early detection and overall survival over the past decade. Current treatment paradigms, with chemotherapy and biologics, appear to have reached their maximum benefit. Immunotherapy, especially with checkpoint inhibitors, has shown considerable clinical benefit in various cancers, including mismatch-repair-deficient CRC. This has led to the planning and initiation of several clinical trials evaluating novel immunotherapy agents-as single agents, combinations and in conjunction with chemotherapy- in patients with CRC. This article reviews biological and preclinical data for checkpoint inhibitors and discusses various immunotherapy trials in CRC, as well as current efforts in CRC immunotherapy.

Original language	English
Pages (from-to)	289-297
Number of pages	9
Journal	Gastroenterology Report
Volume	3
Issue number	4
DOIs	https://doi.org/10.1093/gastro/gov053
State	Published - Nov 1 2015

Keywords

Checkpoint inhibition/blockade
Colorectal cancer
Cytotoxic Tlymphocyte- associated antigen 4 (CTLA-4)
Immunotherapy
Pembrolizumab
Programmed death 1 (PD-1)
Vaccine

Access to Document

10.1093/gastro/gov053

Cite this

@article{d3ccd2e5008543c4803ea8d541ea464c,

title = "Immune checkpoints and immunotherapy for colorectal cancer",

abstract = "Colorectal cancer (CRC) remains one of the major causes of death worldwide, despite steady improvement in early detection and overall survival over the past decade. Current treatment paradigms, with chemotherapy and biologics, appear to have reached their maximum benefit. Immunotherapy, especially with checkpoint inhibitors, has shown considerable clinical benefit in various cancers, including mismatch-repair-deficient CRC. This has led to the planning and initiation of several clinical trials evaluating novel immunotherapy agents-as single agents, combinations and in conjunction with chemotherapy- in patients with CRC. This article reviews biological and preclinical data for checkpoint inhibitors and discusses various immunotherapy trials in CRC, as well as current efforts in CRC immunotherapy.",

keywords = "Checkpoint inhibition/blockade, Colorectal cancer, Cytotoxic Tlymphocyte- associated antigen 4 (CTLA-4), Immunotherapy, Pembrolizumab, Programmed death 1 (PD-1), Vaccine",

author = "Singh, \{Preet Paul\} and Sharma, \{Piyush K.\} and Gayathri Krishnan and Lockhart, \{A. Craig\}",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2015.",

year = "2015",

month = nov,

day = "1",

doi = "10.1093/gastro/gov053",

language = "English",

volume = "3",

pages = "289--297",

journal = "Gastroenterology Report",

issn = "2052-0034",

number = "4",

}

TY - JOUR

T1 - Immune checkpoints and immunotherapy for colorectal cancer

AU - Singh, Preet Paul

AU - Sharma, Piyush K.

AU - Krishnan, Gayathri

AU - Lockhart, A. Craig

N1 - Publisher Copyright: © The Author(s) 2015.

PY - 2015/11/1

Y1 - 2015/11/1

N2 - Colorectal cancer (CRC) remains one of the major causes of death worldwide, despite steady improvement in early detection and overall survival over the past decade. Current treatment paradigms, with chemotherapy and biologics, appear to have reached their maximum benefit. Immunotherapy, especially with checkpoint inhibitors, has shown considerable clinical benefit in various cancers, including mismatch-repair-deficient CRC. This has led to the planning and initiation of several clinical trials evaluating novel immunotherapy agents-as single agents, combinations and in conjunction with chemotherapy- in patients with CRC. This article reviews biological and preclinical data for checkpoint inhibitors and discusses various immunotherapy trials in CRC, as well as current efforts in CRC immunotherapy.

AB - Colorectal cancer (CRC) remains one of the major causes of death worldwide, despite steady improvement in early detection and overall survival over the past decade. Current treatment paradigms, with chemotherapy and biologics, appear to have reached their maximum benefit. Immunotherapy, especially with checkpoint inhibitors, has shown considerable clinical benefit in various cancers, including mismatch-repair-deficient CRC. This has led to the planning and initiation of several clinical trials evaluating novel immunotherapy agents-as single agents, combinations and in conjunction with chemotherapy- in patients with CRC. This article reviews biological and preclinical data for checkpoint inhibitors and discusses various immunotherapy trials in CRC, as well as current efforts in CRC immunotherapy.

KW - Checkpoint inhibition/blockade

KW - Colorectal cancer

KW - Cytotoxic Tlymphocyte- associated antigen 4 (CTLA-4)

KW - Immunotherapy

KW - Pembrolizumab

KW - Programmed death 1 (PD-1)

KW - Vaccine

UR - https://www.scopus.com/pages/publications/85045371624

U2 - 10.1093/gastro/gov053

DO - 10.1093/gastro/gov053

M3 - Review article

AN - SCOPUS:85045371624

SN - 2052-0034

VL - 3

SP - 289

EP - 297

JO - Gastroenterology Report

JF - Gastroenterology Report

IS - 4

ER -

Immune checkpoints and immunotherapy for colorectal cancer

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this